Sinovac's covid vaccine triggers quick immune response after Pfizer’s 90% efficacy
According to the preliminary trial results released on Wednesday, Sinovac Biotech’s experimental COVID-19 vaccine, CoronaVac, induced a quick immune response although its effectiveness cannot be determined as it is in the early to mid-stage clinical trials, per Reuters.
Sinovac is currently running three Phase III trials in Indonesia, Brazil and Turkey.
Additional details
“Our findings show that CoronaVac is capable of inducing a quick antibody response within four weeks of immunization by giving two doses of the vaccine at a 14-day interval.”
“We believe that this makes the vaccine suitable for emergency use during the pandemic.”
Over the past week, American pharma giants Pfizer and Moderna have shown that their covid vaccine has over 90% effective based on interim data from large, late-stage trials.
Meanwhile, the US Food and Drug Administration (FDA) FDA authorized its first COVID-19 test for self-testing at home called Lucira. It's an all-in-one test kit test authorized with self-collected nasal swab samples.
Market reaction
Despite the encouraging vaccine news, the risk sentiment remains tepid amid rising coronavirus cases and new restrictions globally.
The haven demand for the greenback is on the rise while S&P 500 futures extend losses below 3,600.
Related reads
Author
Dhwani Mehta
FXStreet
Residing in Mumbai (India), Dhwani is a Senior Analyst and Manager of the Asian session at FXStreet. She has over 10 years of experience in analyzing and covering the global financial markets, with specialization in Forex and commodities markets.
